
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
This discussion explores the treatments available for managing fibromyalgia symptoms and evaluates the efficacy of antidepressants, including SNRIs, in alleviating pain and other related symptoms.
Video content above is prompted by the following: